Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05988034 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants
A Phase 1 study of Electrocardiography, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT05988034 is a Phase 1 study of Electrocardiography that has completed, run by Amgen. The registered enrollment target is 58 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05988034, a Phase 1 study of Electrocardiography, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to evaluate the effects of therapeutic and supratherapeutic doses of avacopan on the heart rate corrected QT interval, using Fridericia's formula (QTcF).
Conditions Studied
Interventions
- DRUG Moxifloxacin
- DRUG Avacopan
- DRUG Placebo for avacopan
- DRUG Placebo for moxifloxacin
Study Locations (1)
Arizona
- Celerion - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2019-11-08 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05988034
The ClinicalTrials.gov registry entry for NCT05988034 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Electrocardiography appearing as the primary indexed condition, and to 4 interventions - of which Moxifloxacin is the first listed.
NCT05988034 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT05988034 about?
NCT05988034 is a clinical study titled "A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants". The primary objective of this study is to evaluate the effects of therapeutic and supratherapeutic doses of avacopan on the heart rate corrected QT interval, using Fridericia's formula (QTcF).
What is the current status of trial NCT05988034?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2019-11-08. Estimated completion is 2020-03-31.
What conditions does trial NCT05988034 study?
This clinical trial studies the following conditions: Electrocardiography.
What interventions are being tested in trial NCT05988034?
The interventions under investigation include: Moxifloxacin (DRUG), Avacopan (DRUG), Placebo for avacopan (DRUG), Placebo for moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT05988034?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05988034 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Electrocardiography
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.